Located in the Research Triangle Park in North Carolina, Avioq, Inc. is a medical device company established to develop and market high-quality immunodiagnostic products. On September 21, 2009, Avioq’s first product, the Avioq HIV-1 Microelisa System, received FDA’s approval for its use as an aid in diagnosis of infection with HIV-1. On March 27, 2012, Avioq received FDA approval for its HTLV-I/II microelisa system.
Mission and Philosophy
Avioq’s mission is to develop advanced immunodiagnostic products, and to provide the highest quality service to its worldwide customers.
At Avioq, we are passionate about global public health, and we are committed to working closely with our customers to meet their needs.
Retroviral Diagnostics - HIV
Value of Human Immunodeficiency Virus (HIV) Diagnostics
Despite advances in treatment, the HIV/Acquired Immunodeficiency Syndrome (AIDS) pandemic remains one of the biggest challenges for global public health care. Because there is currently no cure for HIV infection, early detection is critical to control the continued spread of HIV infection. The ability to test multiple specimen types provides antibody testing at alternate test sites to enable earlier detection.
Avioq HIV-1 Screening Tests
The Avioq HIV-1 Microelisa System is currently the only assay FDA approved for use with Oral Fluid and Dried Blood Spot specimens. The same product is utilized for testing four different specimen types: serum, plasma, dried blood spots, and oral fluid. Product enhancements provide increased adaptability to automated instrumentation.
Antibody testing with Serum, Plasma, Oral Fluid, and Dried Blood Spots at Reference Laboratories, Departments of Health, Hospitals, Insurance Laboratories, and other Laboratories performing HIV-1 diagnostic testing.
Retroviral Diagnostics - HTLV-I/II
Value of Human T-Lymphotropic Virus Type I (HTLV-I) and/or Human T-Lymphotropic Virus Type II (HTLV-II)
Transmission of HTLV-I and HTLV-II infections to transfusion recipients of infected cellular blood products is well documented. Other known modes of transmission include breast milk, sexual contact, and sharing of contaminated needles and syringes by intravenous drug abusers. Perinatal transmission is suspected but remains unproven.
Avioq HTLV-I/II Screening Tests
The Avioq HTLV-I/II Microelisa System is currently available for the detection of antibodies to HTLV-I and HTLV-II. Product enhancements provide increased adaptability to automated instrumentation.
Antibody testing with Serum or Plasma at Reference Laboratories, Transplantation Labs, Hospitals, Blood Banks, and other Laboratories performing HTLV-I/II diagnostic testing.